Amedica to Present Research Supporting Favorable Silicon Nitride Findings at the Orthopaedic Research Society Annual Meeting
January 28 2016 - 9:00AM
Amedica Corporation (Nasdaq:AMDA), a company that develops and
commercializes silicon nitride ceramics as a biomaterial platform,
is pleased to announce all four submissions to the Orthopaedic
Research Society (“ORS”) Annual Meeting were accepted for
presentation occurring March 5-8, 2016 in Orlando, Florida.
“Our presentations will demonstrate the
rationale for using our proprietary silicon nitride composition in
a variety of medical applications within the $15 billion surgical
spine, dental, hip and knee replacement markets,” said Dr. Sonny
Bal, Chairman and CEO of Amedica Corporation. “This scientific
data will convincingly demonstrate the serious limitations of other
existing biomaterials, while highlighting the advantages of silicon
nitride, even as we continue further testing on an improved second
generation silicon nitride composition. I’m very proud of our
continued innovation and robust science, which will be presented at
this important orthopedic forum.”
Accepted submission titles and their authors
include:
- Metal Ions Contribute to the Material Instability of Zirconia
Toughened Alumina - Giuseppe Pezzotti, Leonardo Puppulin, Marco
Boffelli, Nobuhiko Sugano, Bryan J. McEntire (Presenter), and B.
Sonny Bal
- Differential Bacterial Expression on Silicon Nitride, PEEK, and
Titanium Surfaces - Bryan J. McEntire (Presenter), Erin N. Jones,
Darin Ray, Ryan M. Bock, B.Sonny Bal, and Giuseppe Pezzotti
- Do Ceramic Femoral Heads Contribute to Polyethylene Oxidation?
- Bryan J. McEntire (Presenter), Yuto Enomoto, Wenliang Zhu, Marco
Boffelli, Elia Marin, B. Sonny Bal, and Giuseppe Pezzotti
- Differential Effects of Hydrothermal Ageing on the Surface
Fracture Toughness of Ceramics - Bryan J. McEntire (Presenter),
Erin N. Jones, Darin Ray, Ryan M. Bock, B.Sonny Bal, and Giuseppe
Pezzotti
The ORS annual meeting attracts attendees from
all over the world—clinicians, surgeons, residents, veterinarians,
basic scientists, and engineers who come together to present the
latest innovative and cutting-edge musculoskeletal research.
About Amedica
CorporationAmedica is focused on the development and
application of interbody implants manufactured with medical-grade
silicon nitride ceramic. Amedica markets spinal fusion products and
is developing a new generation of wear- and corrosion-resistant
implant components for hip and knee arthroplasty as well as dental
applications. The Company’s products are manufactured in its ISO
13485 certified manufacturing facility and through its partnership
with Kyocera, one of the world's largest ceramic manufacturers.
Amedica's spine products are FDA-cleared, CE-marked, and are
currently marketed in the U.S. and select markets in Europe and
South America through its distributor network and its growing OEM
and private label partnerships.
For more information on Amedica
or its silicon nitride material platform, please
visit www.amedica.com.
About Orthopaedic Research SocietyOrthopaedic
Research Society (ORS) exists to promote, support, develop and
encourage research in surgery and musculoskeletal disease and
disciplines. Every year, the ORS meeting attracts over 3,000
attendees with an interest in orthopaedic research including
clinicians, surgeons, residents, veterinarians, basic scientists,
and engineers.
Forward-Looking Statements This
press release contains statements that constitute forward-looking
statements within the meaning of the Securities Act of 1933 and the
Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements contained in this press release include, but are not
limited to, the intent, belief or current expectations of Amedica
and members of its management team with respect to Amedica's future
performance, business operations and acceptance of its technology
platform. Statements relating to Amedica's market opportunities,
growth, future products, market acceptance of its products, sales
and financial results and similar statements are subject to risks
and uncertainties such as the timing and success of new product
introductions, physician acceptance, endorsement, and use of
Amedica's products, regulatory matters, competitor activities,
changes in and adoption of reimbursement rates, potential product
recalls, effects of global economic conditions and changes in
foreign currency exchange rates. Additional factors that could
cause actual results to differ materially from those contemplated
within this press release can also be found in Amedica's Risk
Factors disclosure in its Annual Report on Form 10-K, filed with
the Securities and Exchange Commission (SEC) on March 24, 2015, and
in Amedica's other filings with the SEC. Amedica disclaims any
obligation to update any forward-looking statements.
Contacts:Mike HoustonVP,
Commercialization 801-839-3534IR@amedica.com
Robert HaagIRTH
Communications866-976-4784amda@irthcommunications.com
AMEDICA CORP (NASDAQ:AMDA)
Historical Stock Chart
From Mar 2024 to Apr 2024
AMEDICA CORP (NASDAQ:AMDA)
Historical Stock Chart
From Apr 2023 to Apr 2024